| Year |
Citation |
Score |
| 2022 |
Adebayo OO, Dammer EB, Dill CD, Adebayo AO, Oseni SO, Griffen TL, Ohandjo AQ, Yan F, Jain S, Barwick BG, Singh R, Boise LH, Lillard JW. Multivariant Transcriptome Analysis Identifies Modules and Hub Genes Associated with Poor Outcomes in Newly Diagnosed Multiple Myeloma Patients. Cancers. 14. PMID 35565356 DOI: 10.3390/cancers14092228 |
0.643 |
|
| 2021 |
Griffen TL, Dammer EB, Dill CD, Carey KM, Young CD, Nunez SK, Ohandjo AQ, Kornblau SM, Lillard JW. Multivariate transcriptome analysis identifies networks and key drivers of chronic lymphocytic leukemia relapse risk and patient survival. Bmc Medical Genomics. 14: 171. PMID 34187466 DOI: 10.1186/s12920-021-01012-y |
0.671 |
|
| 2021 |
Dill CD, Dammer EB, Griffen TL, Seyfried NT, Lillard JW. A network approach reveals driver genes associated with survival of patients with triple-negative breast cancer. Iscience. 24: 102451. PMID 34007962 DOI: 10.1016/j.isci.2021.102451 |
0.796 |
|
| 2019 |
Ohandjo AQ, Liu Z, Dammer EB, Dill CD, Griffen TL, Carey KM, Hinton DE, Meller R, Lillard JW. Transcriptome Network Analysis Identifies CXCL13-CXCR5 Signaling Modules in the Prostate Tumor Immune Microenvironment. Scientific Reports. 9: 14963. PMID 31628349 DOI: 10.1038/S41598-019-46491-3 |
0.724 |
|
| 2019 |
Adebayo OO, Griffin T, Young C, Dill CD, Nunez S, Carey K, Lillard JW. Abstract LB-132: The role of CXCL13, its sole receptor CXCR5, and associated genes in multiple myeloma progression Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Lb-132 |
0.773 |
|
| 2019 |
Dill CD, Griffen T, Young C, Carey K, Lillard JW. Abstract 1975: Multivariate exome analysis identifies CXCR5-CXCL13 signaling as a key driver in early breast cancer development and prognosis Cancer Research. 79: 1975-1975. DOI: 10.1158/1538-7445.Sabcs18-1975 |
0.767 |
|
| 2019 |
Griffen T, Young C, Dill CD, Carey K, Adebayo O, Nunez S, Lillard J. Abstract 1972: CXCR5-CXCL13 signaling contributes to CLL relapse and patient survival Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1972 |
0.753 |
|
| 2019 |
Carey K, Griffen T, Young C, Dill C, Lillard J. Abstract 1971: A multi-variate transcriptome analysis of CXCR5-CXCL13 signaling in ovarian cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1971 |
0.733 |
|
| 2018 |
Ohandjo AQ, Dill C, Dongquan C, Lillard JW. Abstract B56: Regulation of CXCR5-CXCL13 signaling in prostate cancer etiologic disparities Cancer Epidemiology, Biomarkers & Prevention. 27. DOI: 10.1158/1538-7755.Disp17-B56 |
0.598 |
|
| 2018 |
Dill CD, Okoro A, Chen D, Lillard JW. Abstract B50: The role of CXCL13-CXCR5 signaling in triple-negative breast cancer progression Cancer Epidemiology, Biomarkers & Prevention. 27. DOI: 10.1158/1538-7755.Disp17-B50 |
0.66 |
|
| 2017 |
Candelaria P, Harmon T, Harbuzariu A, Rampoldi A, Lipsey C, Mullen M, Kurian A, Dill C, Tchio C, Daley-Brown D, Nunez S, Lanier V, Gonzalez-Perez RR. Abstract B66: Novel adjuvant therapy for obesity-related cancers Cancer Epidemiology, Biomarkers & Prevention. 26. DOI: 10.1158/1538-7755.Disp16-B66 |
0.367 |
|
| 2016 |
Lipsey CC, Harbuzariu A, Dill C, Gonzalez-Perez RR. Abstract B96: Tackling obesity-related cancer health disparity, new inhibitors of leptin signaling Cancer Epidemiology, Biomarkers & Prevention. 25. DOI: 10.1158/1538-7755.Disp15-B96 |
0.396 |
|
| 2016 |
Harmon TL, Harbuzariu A, Rampoldi A, Dill C, Lanier V, Daley-Brown D, Lipsey C, Tchio C, Yang L, Gonzalez-Perez RR. Abstract 2079: IONP-LPrA2 and PEG-LPrA2 therapies for triple negative breast cancer Cancer Research. 76: 2079-2079. DOI: 10.1158/1538-7445.Am2016-2079 |
0.338 |
|
| Show low-probability matches. |